BSEKabra Drugs LtdLowNeutral
Announced Sat, 6 Sept · 17:41 IST

Notice of 36th Annual General Meeting

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Kabra Drugs Ltd has issued the notice for its 36th Annual General Meeting to be held on Tuesday, September 30, 2025, at 9:00 AM at Ginger Hotel, Indore, Madhya Pradesh. The ordinary business includes adopting the audited financial statements for FY ended March 31, 2025, and re-appointing Mr. Kuniamuthur Nanjappan Anand (DIN: 03230186), who retires by rotation. The special business includes a special resolution to approve remuneration of up to Rs. 14,00,000 per annum to the executive director, and an ordinary resolution to appoint Mr. Tanuj Jain Susilkumar as Secretarial Auditor for a five-year term from FY 2025-26 to FY 2029-30. As per the disclosed financials, the company reported a total revenue of Rs. 64.02 lakhs and a loss after tax of Rs. 108.56 lakhs (EPS of -0.99) for FY 2024-25, with management attributing the loss to higher raw material costs, compliance costs, and competitive pricing. E-voting will be available from September 27 to September 29, 2025, with the cut-off date set as September 23, 2025.

Likely market impact

This is a routine AGM notice with standard governance items, but shareholders should note that the company is seeking approval to pay director remuneration despite posting losses in FY25. The disclosures point to ongoing financial stress, with management expecting commercial production commencement by March 31, 2026, which is a key milestone for future revenue recovery. Investors should review the FY25 results and the company's turnaround plan before voting.